Clinical Trial Update: Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Tempol to prevent radiotherapy-induced alopecia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia

Drugs mentioned

• Tempol (4-hydroxy-TEMPO)

Snippet

Sponsor: Mitos Pharmaceuticals | Conditions: Alopecia | Phase 2 | Status: UNKNOWN